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Introduction
The clinical outcome is generally positive for patients with
node-negative breast carcinoma (i.e. those patients
without detectable metastases in the lymph nodes) who
have been treated with surgery or with surgery and radia-
tion therapy. The disease spreads in about 13% of the
patients, however, and their lives are at risk of death [1–3].
Genetic tests capable of identifying patients at risk for
metastatic spread and/or better treatment targeted to
eradicate metastatic tumor deposits could have a dramatic
impact on the overall survival of these patients.
The construction of a panel of molecular genetic markers
for identifying the 13% lymph node-negative mammary car-
cinomas that are prone to develop metastases [3] would
be valuable in indicating those cases in need of early
bp = base pairs; FISH = fluorescence in situ hybridization; LCM = laser capture microdissection; MADS = metastasis-associated DNA sequences;
NCBI = National Center for Biotechnology Information; PCR = polymerase chain reaction; RDA = representational difference analysis; SCM =
single cell microdissection; STS = sequence tagged sites.
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Abstract
Background: Molecular genetic markers to identify the 13%
lymph node-negative mammary carcinomas that are prone to
develop metastases would clearly be of considerable value in
indicating those cases in need of early aggressive therapy.
Methods: Representational difference analysis was used in an
attempt to identify genetic alterations related to breast cancer
metastasis by comparing genomic DNA from microdissected
normal cells and from metastatic cells of ductal breast
carcinoma patients.
Results: Representational difference analysis products yielded
10 unique metastasis-associated DNA sequences (MADS), i.e.
products apparently lost in metastatic cell DNA. Of these
sequences, MADS-IX was found to be lost in the transition
from primary to metastasis in two out of five ductal breast
carcinoma cases. This sequence was localized on
chromosome 10q21 by radiation hybrid mapping and
fluorescence  in situ hybridization. The PTEN gene, which is
also located on chromosome 10q, was detected to be present
by PCR in all five cases. On the contrary, a breast carcinoma
cell line, HCC-1937, which has homozygous loss of a region
encompassing the PTEN gene, showed the presence of
MADS-IX. PCR screening of three additional breast carcinoma
cell lines with known losses in specific chromosomal regions
also showed the presence of MADS-IX.
Conclusion: These data suggest that MADS-IX possibly is part
of a novel candidate metastasis-associated gene located close
to the PTEN gene on chromosome 10q. The first set of PCR
screening in five patient samples indicates that it could be used
as a molecular marker for ductal mammary metastasis.
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aggressive therapy. There would also be considerable
benefit to the 87% of women with mammary carcinomas
who are not likely to metastasize by sparing them the physi-
cal, mental and financial costs of the treatment. In addition,
further knowledge of the genetic mechanisms that play an
important role in metastasis could ultimately lead to the
development of improved therapeutic procedures.
The evidence for the role of gene alterations in promoting
metastasis in general, and in mammary carcinomas in par-
ticular, is still accumulating. It is probable, however, that
like tumorigenicity suppressor genes and oncogenes
many more genes involved in metastasis remain to be dis-
covered since the process is complex, involving a large
number of pathways [4]. Most of the known genetic mech-
anisms involved in the progression of a tumor to the
metastatic state involve the loss of function of genes that
prevent cells from becoming invasive. These are similar to
tumorigenicity suppressor genes, whose loss of wild-type
growth regulatory function leads to unregulated or malig-
nant growth. Similarly, the wild-type metastasis suppres-
sor genes regulate the cell’s mobility and its response to
environmental messages, presumably keeping most cells
localized and differentiated. Mutation or complete loss
(deletion) of the wild-type counterpart of any such gene in
a malignant cell may make that cell more motile, invasive
or metastatic. In particular, mutations of genes regulating
cell adhesion molecules have been reported to be metas-
tasis-fostering alterations [5–8]. In human breast cancers,
several other genes have been found to be associated with
metastasis, namely nm23 [9,10], KAI1 [11,12], mta1 [13],
KiSS1 [14], PTEN/MMAC1 [15,16] and BRMS1 [17].
Representational difference analysis (RDA), a DNA sub-
tractive hybridization method [18], was used in the
present study to test the working hypothesis that, to
achieve the metastatic state, primary mammary carcinoma
cells must acquire genetic changes in addition to those
changes that led to transformation. With the RDA method,
DNA from normal cells was compared with that of the
metastatic cells of the same patient. The recovered differ-
ential sequences were then mapped on human chromo-
somes and used to screen DNA samples from normal,
primary and metastatic cells of five additional ductal
mammary carcinoma patients to determine whether these
sequences were consistently associated with metastasis.
Materials and methods
Tissue samples and cell lines
Normal breast tissue and lymph nodes with metastatic
cells of a 52-year-old patient (C-1050) with ductal
mammary carcinoma were provided by the Cooperative
Human Tissue Network. Additional matched normal,
primary and metastatic tissue samples were collected
from four patients (patient 1, C-18805; patient 2,
C-98-05H; patient 3, C-19898; and patient 4, C-20635)
from the Cooperative Human Tissue Network and from
one patient (patient 5, DS-9605) from the Surgical Pathol-
ogy Department of Albert Einstein College of Medicine
and Montefiore Medical Center. The DNA samples from
mammary carcinoma cell lines (HCC-1806, HCC-11433,
HCC-1428 and HCC-1937) and matched normal cell
lines were received from Dr R Parson of Columbia Univer-
sity, New York, USA.
Isolation of cells from biopsy samples by single cell
microdissection
Single cell microdissection (SCM) was performed on
hematoxylin and eosin-stained tissue sections of positive
lymph nodes from the ductal breast cancer patient
samples [19]. In the present method of SCM, a Zeiss
axiovert phase contrast photomicroscope fitted with a
television monitor and a Narashige mechanical microdis-
sector was used. A glass micropipette was used to draw
up individual cells after dissection.
Tumor cells were identified in the microscope and, using
the tip of a glass micropipette attached to a syringe, they
were dissected out without disturbing the surrounding
tissue and were then drawn into the pipette. After five to
10 cells were collected in the tip, it was broken off and
dropped into a sterile eppendorf tube. Approximately
10,000 metastatic tumor cells were collected in this
manner for RDA experiments. The SCM method was used
to isolate tumor cells for the RDA experiment because
laser-capture microdissection (LCM) equipment was ini-
tially not available.
Isolation of cells from biopsy samples by LCM
LCM [20] was used for isolating tumor cells from primary
and metastatic tissue samples of additional patients for
screening candidate metastasis-associated DNA
sequences (MADS) by PCR. After many tumor cells have
been captured on the LCM cap, it is then placed on a
500µl PCR tube containing ATL lysis buffer (Qiagen Inc,
Valencia, CA, USA) and the DNA is extracted.
DNA extraction
About 1µg DNA was isolated from approximately 10,000
cells microdissected from metastatic tumor and normal
(glandular and stromal) breast tissue samples, using a
modified method of DNA extraction from archival tissues.
Briefly, the microdissected cell pellet was incubated
overnight in lysis buffer (Qiagen Inc) with proteinase-K at
55°C. Glycogen (carrier) was added to the cell lysate and
DNA was extracted using a phenol–chloroform–isoamyl
alcohol mixture followed by ethanol precipitation [19].
RDA and characterization of differential products
The RDA procedure was basically as described by Lisit-
syn and coworkers [18,21] using the BglII representation.
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and the DNA from the normal cells was the ‘tester’. Three
rounds of hybridization were performed to subtract the
common sequences. The primers used for representation
and hybridization steps of RDA are presented in Table 1.
DNA from the differential bands (lost in metastasis) was
cloned using the TA cloning system (pCR2.1; Invitrogen
Co, Carlsbad, CA, USA). Clones were selected at random
and used as α32P-dCTP (Amersham Biosciences Corp,
Piscataway, NY, USA) probes on dot blots or Southern
blots containing amplicon DNA from the original normal
and metastatic cells to verify whether these sequences are
actually present in the normal cell DNA sample and
missing in the metastatic cell DNA samples. Positive
clones (showing signals in normal cell DNA and missing in
metastatic cell DNA) were sequenced. A homology search
was performed using the National Center for Biotechnol-
ogy Information, National Institutes for Health, USA
(NCBI) Blast program and physical mapping.
Radiation hybrid mapping
Radiation hybrid mapping was used to localize the MADS
on human chromosomes using high-resolution Gene-
Bridge 4 radiation hybrid panels (Research Genetics, Inc ,
Carlsbad, CA, USA). Based on the sequences of differen-
tial products isolated from RDA experiments, 10 pairs of
PCR primers were designed for 10 groups of candidate
gene sequences. Based on the PCR results, chromosome
localization of these sequences was determined using the
Whitehead Institute/MIT databases [22].
Fluorescence in situ hybridization of MADS-IX
Chromosome preparations were made from phytohemag-
glutinin-stimulated peripheral blood lymphocyte cultures
from normal individuals. The slides were fixed in
methanol–acetic acid and were air-dried. The probes used
for fluorescence in situ hybridization (FISH) were the
Spectrum Green labeled centromere of 8 (Vysis, Downers
Grove, IL, USA) and the Spectrum Green labeled 2kb
sized MADS-IX sequence. Primers were designed from
the BAC clone (NCBI, NIH, USA, RP11-407) containing
the MADS-IX sequence to obtain a 2kb sized PCR
product encompassing the MADS-IX region (Table 1).
The 2kb DNA fragment was run on a 1% gel, isolated
from gel and eluted in water, and was labeled with Spec-
trum Green using the nick translation method, following
the manufacturer’s instructions (Vysis). Three-day-old
slides were denatured in 70% formamide/2×SSC
(sodium citrate/chloride) solution at 74°C. The dehydrated
and air-dried slides were used for hybridization according
to published methods with some modifications [23,24].
The slides were counter-stained with 4,6-diamidino-2-
phenylindole dihydrochloride (Molecular Probes, Eugene,
OR, USA) and images were captured on the Nikon E800
using the Quips Pathvysion system (Applied Imaging,
Santa Clara, CA, USA).
Results
Isolation of candidate MADS
RDA was performed with the DNA recovered by SCM
from normal cells and from metastatic cells in the lymph
nodes of a patient with ductal mammary carcinoma. Since
the objective was to isolate sequences that are lost in the
progression of cells from normal to metastasis, we
focused on the products of RDA in which the metastatic
cell DNA was used as the driver and the normal cell DNA
was the tester.
As shown in Fig.1, RDA differential products were isolated
and DNA was extracted from each of the five bands
obtained from the loss side of the third round of hybridiza-
tion, and DNA from each band was cloned separately. One
hundred clones from each DNA band were saved and a
subset of 100 clones (20 clones from each differential
product) was selected randomly for further characterization.
These 100 clones were probed (labeled with α32P-dCTP)
on dot blots containing normal cell DNA and metastatic cell
DNA. It was found that 79 clones hybridized only with the
normal cell DNA and did not hybridize with DNA from the
metastatic cells (Fig.2a). The remaining clones hybridized
with both normal cell DNA and the metastatic cell DNA.
This may have been due to incomplete subtraction. Of the
79 clones that hybridized only with the DNA of the normal
cells, 50 were selected and tested further by Southern blot-
ting to verify the RDA results. None of these clones
hybridized with the DNA of the metastatic cells, and all were
detected in normal cells (Fig.2b).
Sequencing and homology search of candidate MADS
RDA derived 50 clones that were sequenced and those
with identical sequences were grouped. Ten unique candi-
date MADS were thus identified. The sequence homolo-
gies found by searching the nucleotide databases of these
MADS are presented in Table 2. The search revealed that
these MADS have homology with sequences on chromo-
some 1 (MADS-III), chromosome 5 (MADS-I), chromo-
some 6 (MADS-VII and MADS-VIII), chromosome 7
(MADS-VI), chromosome 10 (MADS-IX), chromosome 15
(MADS-X), chromosome 16 (MADS-V) and chromo-
some 21 (MADS-II). Nine of these MADS have about
82–99% homology to known human DNA sequences, and
the remaining MADS-IV was found to be novel, having no
homology with the sequences in the gene banks.
Radiation hybrid mapping of MADS
We used the GeneBridge 4 Radiation Hybrid panel
(Research Genetics, Inc) to localize these 10 MADS on
human chromosomes. For this physical mapping, and also
to be able to use these sequences to screen additional
patient samples, primer pairs were designed for each
sequence and tested by PCR on a positive control (human
genomic DNA) and on two negative controls (Chinese
hamster genomic DNA and no template). Of the 10 MADSAvailable online http://breast-cancer-research.com/content/5/2/R52
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tested, only five (MADS-IV, MADS-VII, MADS-VIII,
MADS-IX and MADS-X) were successfully mapped to
specific human chromosomes (Table 2). Of these five
MADS, MADS-IV did not show any match with gene bank
sequences and therefore appeared to be a novel DNA
sequence. The chromosome localizations for MADS-VII,
MADS-VIII, MADS-IX and MADS-X obtained by physical
mapping and by homology search data were in agree-
ment.
Further characterization of MADS-IX
While the homology results of MADS-IX revealed that it
has 94% homology with the sequence on chromo-
some 10q (BAC-AC022541.10), the radiation hybrid
mapping showed that MADS-IX is localized to a 21cR
interval between markers D105539 and D10S549, corre-
sponding to human chromosome 10 band q21.1 [25]. To
confirm that MADS-IX is not an artifact and is actually a
human DNA sequence located on chromosome 10q, we
used the sequence as a fluorescence in situ hybridization
probe on human metaphase chromosomes. Based on the
sequence of the BAC clone (NCBI, RP11-407) encom-
passing MADS-IX, a 2kb DNA fragment containing
MADS-IX was generated by PCR. To localize MADS-IX
cytologically, we labeled the 2kb sized MADS-IX with
Spectrum Green (Vysis) and hybridized on normal human
metaphase chromosomes. Figure 3 shows that the
MADS-IX probe was hybridized on the 10q21 region. The
Spectrum Green labeled centromere of chromosome 8
(Vysis) was used as a control.
To determine whether MADS-IX is indeed associated with
metastasis, DNA was screened from cells recovered with
the LCM method from normal, primary and metastatic tissue
Table 1
Primers used in representational difference analysis (RDA) and different PCR screening experiments
Primer/product size Primer sequence (forward) Primer sequence (reverse)
RDA representation R24, 5′-agcactctccagcctctcaccgca-3′ R12, 5′-gatctgcggtga-3′
RDA first-round hybridization J24, 5′-accgacgtcgactatccatgaaca-3′ J12, 5′-gatctgttcatg-3′
RDA second-round hybridization N24, 5′-aggcaactgtgctatccgagggaa-3′ N12, 5′-gatcttccctcg-3′
RDA third-round hybridization Same as first round (J24) Same as first round (J12)
PTEN (556 bp) 5′-ctcagattgccttataatagtc-3′ 5′-tcatgttactgctacgtaaac-3′
MADS-IX (180 bp) 5′-aggtaggtagagtaacaggtttgttt-3′ 5′-gatctgttctcccttttctttagctt-3′
FISH fragment (2 kb) 5′-actatgtatgtgagcatctgtttgc-3′ 5′-tgcactcttcacttgagtaaacttg-3′
β-Actin (295 bp) 5′-tcacccacactgtgcccatctacga-3′ 5′-cgacgtagcacagcttctcctta-3′
FISH, fluorescence in situ hybridization.
Figure 1
Isolation of representational difference analysis (RDA) differential
products from single-cell microdissected archival breast tissues. RDA
hybridization was of the normal cell DNA versus the metastatic tumor
cell DNA and was performed in two ways. In the first RDA (lane 2) the
metastatic cell DNA was used as the tester (which should yield
differential sequences gained during malignant transformation or in the
process of becoming metastatic), and in the second RDA (lane 3)
normal DNA was used as the tester (which should yield sequences
that were lost from the metastatic cells). (a), (b) and (c) Three rounds
of RDA hybridizations were performed. In the third round of
hybridization, the ‘gain’ lane contained four DNA bands (faint fourth
band) ranging from 200 to 300bp in size (c, lane 2) whereas in the
‘loss’ lane there are five bands (faint fourth band) ranging from 200 to
370bp (c, lane 3) in size (arrows). Lane 1, low molecular weight DNA
marker (2kb).
Figure 2
Southern blot analysis using MADS-IX as an α32P-dCTP probe on
normal amplicon DNA and on metastatic amplicon DNA. (a) A dot blot
and (b) a Southern blot showing positive signals only in the normal cell
DNA (N) but not in the metastatic cell DNA (M).samples from five additional patients. Because MADS-IX
was mapped to chromosome 10q21, we also wanted to
determine whether it was located in the region encompass-
ing a well-known metastasis-associated gene, PTEN [15].
First, DNA samples from these five patients were
screened by PCR using primers designed for MADS-IX
and PTEN. MADS-IX showed PCR amplification in normal
cell DNA samples of all the five patients, but the intensities
of the PCR bands were less in the primary tumor cell DNA
samples and were totally undetectable in the metastatic
cell DNA of patients 1 and 3 (Fig.4). The PTEN gene, on
the contrary, was detected, without any difference in the
intensity of PCR bands in the DNA samples of normal
Breast Cancer Research    Vol 5 No 2 Achary et al.
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Table 2
The length, homology search and radiation hybrid mapping results of the metastasis-associated DNA sequences (MADS)
MADS Length (bp) Homology Radiation hybrid mapping
MADS-I 205 Chromosome 5 (97%) AC005915.1 Not successful
MADS-II 144 Chromosome 21 (99%) AC010463.6 Not successful
MADS-III 277 Chromosome 1 (97%) AL359265.8 Not successful
MADS-IV 185 No match Chromosome 5; places 19.72 cR from WI-6737
MADS-V 220 Chromosome 16 (98%) AC004234.1 Not successful
MADS-VI 242 Chromosome 7 (97%) AC09333.1 Not successful
MADS-VII 190 Chromosome 6 (98%) AL121935.17 Chromosome 6; places 1.51 cR from WI-3110
MADS-VIII 170 Chromosome 6 (82%) AC013429.12 Chromosome 6; places 3.67 cR from AFMA191WD1
MADS-IX 180 Chromosome 10 (94%) AC022541.10 Chromosome 10; places 5.66 cR from D10S546
MADS-X 192 Chromosome 15 (98%) AC104260.5 Chromosome 15; places 1.71 cR from D15S157
Figure 3
Localization of the 2kb DNA fragment containing MADS-IX on human
metaphase chromosomes. The centromere of chromosome 8 was
used as a positive control probe. MADS-IX was found to localize
around the 10q21 chromosome region (close to the centromere). Both
the MADS-IX and the Spectrum Green labeled centromere of 8 were
labeled with spectrum green (Vysis, Downers Grove, IL, USA), and the
chromosomes were counter-stained by 4,6-diamidino-2-phenylindole
dihydrochloride.
Figure 4
PCR screening of MADS-IX on normal cell DNA, primary cell DNA and
metastatic cell DNA samples of five patients. PCR results show the
target DNA band (180bp) missing in patients 1 and 3. While MADS-IX
showed a reduction in the intensity (about one-half) of the PCR band
(heterozygous loss) in the primary tumors (P) of patients 1 and 3, it is
completely missing (homozygous loss) in their metastatic (M) cell DNA
samples but present in normal cell DNA (N). β-Actin was used as an
internal control.cells, primary tumor cells and metastatic lymph node cells
of all five patients.
Second, MADS-IX and PTEN were screened in four
breast tumor cell lines (HCC-1806, HCC-1143,
HCC-1428 and HCC-1937) and matched normal DNA.
The first three tumor cell lines had known losses in spe-
cific chromosomal regions, and the fourth had loss of
homozygosity of the PTEN gene. PCR screening of
MADS-IX and PTEN showed that MADS-IX is present in
all four tumor cell lines, but PTEN is only present in cell
lines HCC-1806, HCC-1143 and HCC-1428 and is
missing in HCC-1937 (Fig.5).
Discussion
Reports show a statistically significant increase in loss of
heterozygosity events involving unknown genes on chromo-
some 16q [26], on chromosome 10q [15] and on chromo-
some 14q [27], in metastatic breast cancers. Measuring
loss of heterozygosity, O’Connell et al. [27] found that the
majority of lymph node-negative primary breast tumors did
not amplify a region linked to D14S62 and D14S51, while
lymph node-positive breast tumors retained heterozygosity
for these markers. These data could imply the existence of
metastasis promoting gene(s) in that region or, alterna-
tively, the observed molecular changes may be used as a
marker of metastatic propensity [28].
In the present investigation we used RDA in an attempt to
identify genetic alterations related to breast cancer metas-
tasis by comparing normal cell DNA and metastatic cell
DNA of a ductal breast carcinoma patient. Ten unique
candidate MADS were identified and the sequence
homologies found by searching the gene bank of these
MADS are presented in Table 2. The search revealed
82–99% homology to known human gene sequences for
nine of these MADS but MADS-IV was found to be novel,
having no homology with the sequences in the gene
banks. Further characterization of MADS-IX revealed inter-
esting information on the genes and sequence tagged
sites (STS) markers surrounding it. Within a range of
1.4Mb of MADS-IX, we noticed two CDC2 genes (cell
division cycle 2 protein, isoform 1 and isoform 2) and two
splice variants of the ZWINT gene (without known exact
function). In the range of 821kb, there are nine STS
markers (RH26942, SHGC-58267, SHGC-79901,
AFM336XD1, SHGC-103705, SHGC-3856, SHGC-84937,
STSG72171 and SHGC-81245).
Physical and cytological mapping of MADS-IX confirmed
that it is located at 10q21.1. Screening of MADS-IX on
DNA samples from five more sets of normal, primary and
matched metastatic tumor samples (Fig.4) revealed that
MADS-IX is lost in the transition from normal cells to
primary cells to metastasis cells in two of five cases (three
of six cases if the case used in the RDA assay is
included). PCR screening of PTEN on these five patient
samples and screening of MADS-IX and PTEN on a
breast carcinoma cell line that had loss of homozygosity of
the PTEN gene revealed that MADS-IX is neither a part of
the PTEN gene or localized in the homozygous loss region
of chromosome 10q encompassing the PTEN gene.
These findings together strongly suggest that MADS-IX is
a candidate marker for a novel metastasis suppressor
gene. Additional archival cases are being screened to
determine whether MADS-IX is a reliable marker for
metastasis in ductal breast cancers.
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